Total Payments
$434,408
2024 Payments
$18.09
Companies
8
Transactions
55
Medicare Patients
1,550
Medicare Billing
$179,102
Payment Breakdown by Category
Consulting$414,625 (95.4%)
Other$10,700 (2.5%)
Research$6,730 (1.5%)
Travel$1,534 (0.4%)
Food & Beverage$781.03 (0.2%)
Gifts$20.00 (0.0%)
Education$18.09 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $414,625 | 28 | 95.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $7,000 | 2 | 1.6% |
| Unspecified | $6,730 | 3 | 1.5% |
| Honoraria | $3,700 | 3 | 0.9% |
| Travel and Lodging | $1,534 | 7 | 0.4% |
| Food and Beverage | $781.03 | 10 | 0.2% |
| Gift | $20.00 | 1 | 0.0% |
| Education | $18.09 | 1 | 0.0% |
Payments by Type
General
$427,678
52 transactions
Research
$6,730
3 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Research & Development, LLC | $411,750 | 27 | $0 (2022) |
| La Jolla Pharmaceutical Company | $9,888 | 11 | $0 (2018) |
| PFIZER INC. | $6,750 | 4 | $0 (2023) |
| PORTOLA PHARMACEUTICALS, INC. | $2,879 | 8 | $0 (2019) |
| Janssen Scientific Affairs, LLC | $2,875 | 1 | $0 (2021) |
| Kadmon Corporation LLC | $132.48 | 2 | $0 (2017) |
| Genentech USA, Inc. | $115.00 | 1 | $0 (2019) |
| Merck Sharp & Dohme LLC | $18.09 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $18.09 | 1 | Merck Sharp & Dohme LLC ($18.09) |
| 2023 | $3,530 | 2 | PFIZER INC. ($3,530) |
| 2022 | $269,750 | 16 | Janssen Research & Development, LLC ($266,550) |
| 2021 | $148,095 | 14 | Janssen Research & Development, LLC ($145,200) |
| 2019 | $2,994 | 9 | PORTOLA PHARMACEUTICALS, INC. ($2,879) |
| 2018 | $9,888 | 11 | La Jolla Pharmaceutical Company ($9,888) |
| 2017 | $132.48 | 2 | Kadmon Corporation LLC ($132.48) |
All Payment Transactions
55 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 03/08/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Education | In-kind items and services | $18.09 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/13/2023 | PFIZER INC. | COMIRNATY (Biological) | — | In-kind items and services | $3,200.00 | Research |
| Study: BNT162 CLINICAL PUBLICATION PROGRAM • Category: VACCINES | ||||||
| 08/16/2023 | PFIZER INC. | COMIRNATY (Biological) | — | In-kind items and services | $330.00 | Research |
| Study: BNT162 CLINICAL PUBLICATION PROGRAM • Category: VACCINES | ||||||
| 11/01/2022 | PFIZER INC. | PAXLOVID (Drug) | — | In-kind items and services | $3,200.00 | Research |
| Study: COVID19 HOSP CLINICAL PUBLICATION PROGRAM • Category: INFECTIOUS DISEASES | ||||||
| 09/21/2022 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $3,150.00 | General |
| 08/23/2022 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $3,600.00 | General |
| 08/23/2022 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $3,300.00 | General |
| 07/14/2022 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $15,600.00 | General |
| 07/14/2022 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $7,500.00 | General |
| 06/08/2022 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $9,900.00 | General |
| 06/08/2022 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $6,000.00 | General |
| 05/13/2022 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $15,900.00 | General |
| 05/13/2022 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $12,900.00 | General |
| 04/20/2022 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $32,100.00 | General |
| 04/20/2022 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $24,300.00 | General |
| 03/16/2022 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $56,700.00 | General |
| 03/16/2022 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $14,100.00 | General |
| 01/05/2022 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $43,200.00 | General |
| 01/05/2022 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $18,300.00 | General |
| 11/09/2021 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $14,700.00 | General |
| 10/15/2021 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $1,200.00 | General |
| 10/15/2021 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $300.00 | General |
| 09/10/2021 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $14,400.00 | General |
| 09/10/2021 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $2,400.00 | General |
| 08/12/2021 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $42,600.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| BNT162 CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,530 | 2 |
| COVID19 HOSP CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 14 | 439 | 512 | $240,772 | $39,950 |
| 2022 | 13 | 501 | 593 | $213,656 | $38,214 |
| 2021 | 12 | 377 | 554 | $350,039 | $66,809 |
| 2020 | 8 | 233 | 320 | $163,378 | $34,129 |
Total Patients
1,550
Total Services
1,979
Medicare Billing
$179,102
Procedure Codes
55
All Medicare Procedures & Services
55 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 46 | 87 | $91,261 | $15,282 | 16.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 86 | 102 | $51,204 | $7,301 | 14.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 31 | 31 | $21,669 | $3,286 | 15.2% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 24 | 32 | $12,512 | $3,169 | 25.3% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 20 | 20 | $10,862 | $2,161 | 19.9% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 31 | 32 | $8,902 | $2,107 | 23.7% |
| 99292 | Critical care, each additional 30 minutes | Facility | 2023 | 13 | 19 | $9,036 | $1,675 | 18.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 11 | 11 | $9,372 | $1,654 | 17.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 12 | 12 | $7,752 | $1,217 | 15.7% |
| 36556 | Insertion of non-tunneled central venous tube for infusion (5 years or older) | Facility | 2023 | 11 | 12 | $11,292 | $819.24 | 7.3% |
| 94726 | Test to determine lung volumes using sensors | Office | 2023 | 29 | 29 | $1,421 | $287.68 | 20.2% |
| 94726 | Test to determine lung volumes using sensors | Facility | 2023 | 22 | 22 | $1,078 | $218.24 | 20.2% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2023 | 29 | 29 | $1,110 | $212.57 | 19.2% |
| 94729 | Test to examine how well the lungs exchange gases | Facility | 2023 | 23 | 23 | $865.00 | $168.59 | 19.5% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2023 | 16 | 16 | $963.00 | $135.84 | 14.1% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Facility | 2023 | 11 | 11 | $657.00 | $93.39 | 14.2% |
| 94010 | Test to measure expiratory airflow and volume | Facility | 2023 | 13 | 13 | $442.00 | $88.01 | 19.9% |
| 94010 | Test to measure expiratory airflow and volume | Office | 2023 | 11 | 11 | $374.00 | $74.47 | 19.9% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 34 | 94 | $96,744 | $16,699 | 17.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 68 | 82 | $39,964 | $6,410 | 16.0% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 29 | 37 | $14,011 | $3,115 | 22.2% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 15 | 15 | $9,638 | $2,450 | 25.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 21 | 21 | $14,033 | $1,932 | 13.8% |
| 99221 | Initial hospital inpatient care per day, typically 30 minutes | Facility | 2022 | 19 | 19 | $6,954 | $1,487 | 21.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 24 | 27 | $9,218 | $1,405 | 15.2% |
About Timothy Albertson, MD, PHD, MPH
Timothy Albertson, MD, PHD, MPH is a Medical Toxicology healthcare provider based in Sacramento, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/22/2005. The National Provider Identifier (NPI) number assigned to this provider is 1184607236.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Timothy Albertson, MD, PHD, MPH has received a total of $434,408 in payments from pharmaceutical and medical device companies, with $18.09 received in 2024. These payments were reported across 55 transactions from 8 companies. The most common payment nature is "Consulting Fee" ($414,625).
As a Medicare-enrolled provider, Albertson has provided services to 1,550 Medicare beneficiaries, totaling 1,979 services with total Medicare billing of $179,102. Data is available for 4 years (2020–2023), covering 55 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Toxicology
- Other Specialties Critical Care Medicine, Pulmonary Disease
- Location Sacramento, CA
- Active Since 11/22/2005
- Last Updated 09/08/2011
- Taxonomy Code 207PT0002X
- Entity Type Individual
- NPI Number 1184607236
Products in Payments
- GIAPREZA (Drug) $9,888
- COMIRNATY (Biological) $3,530
- PAXLOVID (Drug) $3,200
- ANDEXXA (Biological) $2,879
- WINREVAIR (Biological) $18.09
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.